Compare SYRE & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYRE | ITGR |
|---|---|---|
| Founded | 2013 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2016 | 2000 |
| Metric | SYRE | ITGR |
|---|---|---|
| Price | $33.03 | $78.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $56.50 | ★ $95.00 |
| AVG Volume (30 Days) | ★ 925.8K | 638.6K |
| Earning Date | 11-04-2025 | 10-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.42 |
| Revenue | N/A | ★ $1,831,074,000.00 |
| Revenue This Year | N/A | $9.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $32.07 |
| Revenue Growth | N/A | ★ 9.54 |
| 52 Week Low | $10.91 | $62.00 |
| 52 Week High | $35.31 | $146.36 |
| Indicator | SYRE | ITGR |
|---|---|---|
| Relative Strength Index (RSI) | 62.10 | 63.89 |
| Support Level | $32.50 | $77.30 |
| Resistance Level | $34.84 | $80.69 |
| Average True Range (ATR) | 1.48 | 2.09 |
| MACD | -0.37 | 1.17 |
| Stochastic Oscillator | 25.90 | 81.07 |
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.